Inogen (INGN) Cash from Financing Activities (2013 - 2026)
Inogen's (INGN) quarterly Cash from Financing Activities came in at -$2.1 million in Q1 2026, down 108.86% year-on-year from $24.0 million in Q1 2025, and down 1035.29% on a QoQ basis from -$187000.0 in Q4 2025.
Inogen (INGN) Cash from Financing Activities (2013 - 2026) Analysis & Trends
Inogen (INGN) has 14 years of Cash from Financing Activities data on file, last reported at -$2.1 million in Q1 2026.
- On a quarterly basis, Cash from Financing Activities fell 108.86% year-over-year to -$2.1 million in Q1 2026; TTM through Mar 2026 was -$1.9 million, a 107.91% decrease from a year earlier, with the FY2025 full-year figure at $24.2 million, up 9025.28% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$2.1 million, down from -$187000.0 in the prior quarter.
- Over the last five years, Cash from Financing Activities for INGN reached as high as $24.0 million in Q1 2025 and fell as low as -$2.1 million in Q1 2026.
- Historically, Cash from Financing Activities has averaged $1.5 million across 5 years, with a median of -$23500.0 in 2023.
- Across the five-year window, Cash from Financing Activities plunged 1757.14% in 2024 and jumped 8303.86% in 2025, its largest moves.
- Year by year, Cash from Financing Activities stood at -$112000.0 in 2022, then jumped by 87.5% to -$14000.0 in 2023, then plunged by 1757.14% to -$260000.0 in 2024, then grew by 28.08% to -$187000.0 in 2025, then slumped by 1035.29% to -$2.1 million in 2026.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were -$2.1 million in Q1 2026, -$187000.0 in Q4 2025, and $418000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -25.00 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -26.93 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Inogen | 172.68 Mn | 62.51 Mn | 37.86 Mn | -2.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.12 Mn |
| Mar 31, 2026 | -2.12 Mn |
| Dec 31, 2025 | -187,000.00 |
| Dec 31, 2025 | -187,000.00 |
| Sep 30, 2025 | 418,000.00 |
| Sep 30, 2025 | 418,000.00 |
| Mar 31, 2025 | 23.95 Mn |
| Mar 31, 2025 | 23.95 Mn |
| Dec 31, 2024 | -260,000.00 |
| Dec 31, 2024 | -260,000.00 |
| Sep 30, 2024 | 441,000.00 |
| Sep 30, 2024 | 441,000.00 |
| Jun 30, 2024 | -201,000.00 |
| Jun 30, 2024 | -201,000.00 |
| Mar 31, 2024 | 285,000.00 |
| Mar 31, 2024 | 285,000.00 |
| Dec 31, 2023 | -14,000.00 |
| Dec 31, 2023 | -14,000.00 |
| Sep 30, 2023 | 448,000.00 |
| Sep 30, 2023 | 448,000.00 |